Cargando…

An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients

Anemia is one of the common complications in chronic kidney disease (CKD) patients. Erythropoietin and iron deficiencies are the major causes to develop anemia in CKD patients. Untreated anemia is associated with increased morbidity and mortality. Erythropoietin-stimulating agents (ESA) with iron su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sonia, Shamsun Nahar, George, Sherie, Shahi, Srushti R, Ali, Zahra, Abaza, Abdelrahman, Jamil, Aneeque, Gutlapalli, Sai Dheeraj, Ali, Marya, Oble, Mrinal J P, Yu, Ann Kashmer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436024/ https://www.ncbi.nlm.nih.gov/pubmed/37602095 http://dx.doi.org/10.7759/cureus.42045

Ejemplares similares

Adverse Side Effects of Crizotinib in the Treatment of Anaplastic Lymphoma Kinase-Mutated Non-small Cell Lung Cancer: A Systematic Review
por: George, Sherie, et al.
Publicado: (2023)

Parkinson’s Neuropathology Puzzle: A Systematic Review Uncovering the Pathological Culprits Behind the Neurological Disease
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Effectiveness of Catheter Ablation in Left Ventricular Ejection Fraction, Stroke, Quality of Life, All-Cause Mortality, Sinus Rhythm Maintenance, and Hospitalization Rates as Compared to Medical Therapy
por: Oble, Mrinal J P, et al.
Publicado: (2023)

Meditation and Its Mental and Physical Health Benefits in 2023
por: Jamil, Aneeque, et al.
Publicado: (2023)

A Systematic Review of Quantitative and Qualitative Results of Randomized Controlled Trials Assessing the Effect of Yoga in Adult Women With Post-traumatic Stress Disorder: What Is Known So Far
por: Ali, Marya, et al.
Publicado: (2023)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
por: Joharapurkar, Amit A., et al.
Publicado: (2022)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
por: Zheng, Li, et al.
Publicado: (2022)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
por: Li, Jing, et al.
Publicado: (2022)

Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
por: Grzeszczak, Władysław, et al.
Publicado: (2021)

The role of HIF prolyl hydroxylases in tumour growth
por: Jokilehto, Terhi, et al.
Publicado: (2010)

Function and expression of prolyl hydroxylase 3 in cancers
por: Liu, Qiu-long, et al.
Publicado: (2013)

Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review
por: Damarlapally, Nanush, et al.
Publicado: (2023)

Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle
por: Wish, Jay B.
Publicado: (2021)

Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
por: Zhang, Huifang, et al.
Publicado: (2020)

Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence
por: Fujikawa, Ryo, et al.
Publicado: (2022)

Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
por: Chen, Dinghua, et al.
Publicado: (2023)

Structure and Mechanism of a Viral Collagen Prolyl Hydroxylase
por: Longbotham, James E., et al.
Publicado: (2015)

Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat
por: Figg, William D., et al.
Publicado: (2021)

Role of prolyl hydroxylase domain proteins in bone metabolism
por: Wolf, David, et al.
Publicado: (2022)

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
por: Chen, Nan, et al.
Publicado: (2017)

Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)
por: Noonan, Megan L., et al.
Publicado: (2020)

Prolyl 4 Hydroxylase: A Critical Target in the Pathophysiology of Diseases
por: Kant, Ravi, et al.
Publicado: (2013)

The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma
por: Hatzimichael, E, et al.
Publicado: (2012)

Prolyl-hydroxylase 3: evolving roles for an ancient signaling protein
por: Place, Trenton L, et al.
Publicado: (2013)

Role of prolyl hydroxylase domain proteins in the regulation of insulin secretion
por: Huang, Mei, et al.
Publicado: (2016)

Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism
por: Yang, Ming, et al.
Publicado: (2014)

Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase
por: Yum, Soohwan, et al.
Publicado: (2017)

An Arabidopsis Prolyl 4 Hydroxylase Is Involved in the Low Oxygen Response
por: Konkina, Anna, et al.
Publicado: (2021)

Prolyl 3-Hydroxylase 2 Is a Molecular Player of Angiogenesis
por: Pignata, Paola, et al.
Publicado: (2021)

Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor
por: Wang, Ruth X., et al.
Publicado: (2021)

Inhibition of HIF-prolyl hydroxylases improves healing of intestinal anastomoses
por: Strowitzki, Moritz J., et al.
Publicado: (2021)

Role of prolyl hydroxylase/HIF-1 signaling in vascular calcification
por: Negri, Armando Luis
Publicado: (2022)

Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk
por: Harlow, Charli E, et al.
Publicado: (2022)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
por: Ogawa, Chie, et al.
Publicado: (2023)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
por: Lun, Jie, et al.
Publicado: (2023)

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
por: Yan, Zhipeng, et al.
Publicado: (2020)

Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis
por: Fukuta, Hidekatsu, et al.
Publicado: (2022)

Inactivation of HIF‐prolyl 4‐hydroxylases 1, 2 and 3 in NG2‐expressing cells induces HIF2‐mediated neurovascular expansion independent of erythropoietin
por: Urrutia, Andrés A., et al.
Publicado: (2020)

Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor
por: Kiriakidis, Serafim, et al.
Publicado: (2017)

Obesity and Coronary Artery Disease: An Updated Systematic Review 2022
por: Manoharan, Mohana Priya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ltqad5g77p0fbtkf5p9fmjaa7t